Prolactin receptor expression in lymphocytes from patients with hyperprolactinemia or acromegaly.

Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Prolactin receptor expression in lymphocytes from patients with hyperprolactinemia or acromegaly.

J Endocrinol. 1995 Nov;147(2):353-9. Unique Identifier : AIDSLINE MED/96096308
Leite-de-Moraes MC; Touraine P; Kelly PA; Kuttenn F; Dardenne M; Universite Rene Descartes, Paris V, CNRS URA 1461, Hopital; Necker, Paris, France.

Abstract: Previous reports demonstrated that prolactin receptors (PRL-R) are widely expressed on cells of the immune system. We analyzed a possible regulation of PRL-R expression on human mononucleated blood cells by prolactin (PRL) itself. PRL-R expression was analyzed by immunofluorescence on T and B lymphocytes and monocytes from peripheral blood mononucleated cells (PBMC) of patients with hyperprolactinemia or acromegaly compared with sex- and age-matched control subjects. The frequency of PRL-R positive cells and the intensity of PRL-R expression was only modified among the CD8+ T cell population of hyperprolactinemic patients with macroadenoma. No correlation was reported between PRL-R expression and circulating PRL levels. The percentage of PRL-R+ cells on B or T lymphocytes and monocytes as well as the capacity of PBMC to proliferate in response to T cell mitogens were not significantly different in bromocriptine-treated compared with untreated patients. These findings suggest that factors other than pituitary PRL play the major role in regulating PRL-R expression on cells of the immune system.

Keywords: Acromegaly/DRUG THERAPY/*METABOLISM Adenoma/IMMUNOLOGY/METABOLISM Adult Bromocriptine/THERAPEUTIC USE Cells, Cultured CD8-Positive T-Lymphocytes/METABOLISM/PATHOLOGY Down-Regulation (Physiology) Flow Cytometry Human Hyperprolactinemia/DRUG THERAPY/IMMUNOLOGY/*METABOLISM Lymphocyte Count Lymphocytes/*METABOLISM Middle Age Pituitary Neoplasms/IMMUNOLOGY/METABOLISM Receptors, Prolactin/DRUG EFFECTS/*METABOLISM Support, Non-U.S. Gov't JOURNAL ARTICLE
960330
M9630680

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .